Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation

M. Picardi, C. Selleri, G. De Rosa, A. Raiola, L. Pezzullo, B. Rotoli

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The risk of severe hepatic damage in patients with chronic hepatitis B virus (HBV) infection is well known; more effective treatments for this infection are needed. Lamivudine is being studied in immunocompetent and immunosuppressed HBV infected patients. We report a patient suffering from chronic replicative HBV infection after allogeneic BMT, who responded to lamivudine therapy. A 24-year-old woman with CML received an allogeneic BMT from her HLA-identical sister in June 1992. Before transplant, her HBV status demonstrated viral contact without active infection (HBsAb+, HBcAb+ IgG, HBeAb+). Four months after BMT mild chronic liver GVHD appeared, requiring immunosuppressive treatment. Antibodies to HBV completely disappeared post-transplant. Acute icteric hepatitis occurred 2 years later, with HBsAg+, high level of HBV-DNA, HBeAg+ and HBcAb IgM+. Lamivudine 100 mg/day rapidly reduced transaminase levels and effected HBV-DNA disappearance within 2 months. The treatment was well tolerated; no hematological side-effects occurred. This preliminary observation warrants further investigation of lamivudine treatment in bone marrow transplanted patients with active HBV infection.

Original languageEnglish
Pages (from-to)1267-1269
Number of pages3
JournalBone Marrow Transplantation
Volume21
Issue number12
Publication statusPublished - 1998

Fingerprint

Lamivudine
Homologous Transplantation
Chronic Hepatitis B
Virus Diseases
Bone Marrow Transplantation
Hepatitis B virus
Therapeutics
Transplants
Hepatitis B Antibodies
Hepatitis B e Antigens
Liver
DNA
Immunosuppressive Agents
Hepatitis B Surface Antigens
Transaminases
Infection
Hepatitis
Immunoglobulin M
Siblings
Immunoglobulin G

Keywords

  • Bone marrow transplantation
  • Chronic hepatitis B virus infection
  • Lamivudine

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. / Picardi, M.; Selleri, C.; De Rosa, G.; Raiola, A.; Pezzullo, L.; Rotoli, B.

In: Bone Marrow Transplantation, Vol. 21, No. 12, 1998, p. 1267-1269.

Research output: Contribution to journalArticle

Picardi, M. ; Selleri, C. ; De Rosa, G. ; Raiola, A. ; Pezzullo, L. ; Rotoli, B. / Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. In: Bone Marrow Transplantation. 1998 ; Vol. 21, No. 12. pp. 1267-1269.
@article{b4d10780ee264833a80486d55359da83,
title = "Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation",
abstract = "The risk of severe hepatic damage in patients with chronic hepatitis B virus (HBV) infection is well known; more effective treatments for this infection are needed. Lamivudine is being studied in immunocompetent and immunosuppressed HBV infected patients. We report a patient suffering from chronic replicative HBV infection after allogeneic BMT, who responded to lamivudine therapy. A 24-year-old woman with CML received an allogeneic BMT from her HLA-identical sister in June 1992. Before transplant, her HBV status demonstrated viral contact without active infection (HBsAb+, HBcAb+ IgG, HBeAb+). Four months after BMT mild chronic liver GVHD appeared, requiring immunosuppressive treatment. Antibodies to HBV completely disappeared post-transplant. Acute icteric hepatitis occurred 2 years later, with HBsAg+, high level of HBV-DNA, HBeAg+ and HBcAb IgM+. Lamivudine 100 mg/day rapidly reduced transaminase levels and effected HBV-DNA disappearance within 2 months. The treatment was well tolerated; no hematological side-effects occurred. This preliminary observation warrants further investigation of lamivudine treatment in bone marrow transplanted patients with active HBV infection.",
keywords = "Bone marrow transplantation, Chronic hepatitis B virus infection, Lamivudine",
author = "M. Picardi and C. Selleri and {De Rosa}, G. and A. Raiola and L. Pezzullo and B. Rotoli",
year = "1998",
language = "English",
volume = "21",
pages = "1267--1269",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation

AU - Picardi, M.

AU - Selleri, C.

AU - De Rosa, G.

AU - Raiola, A.

AU - Pezzullo, L.

AU - Rotoli, B.

PY - 1998

Y1 - 1998

N2 - The risk of severe hepatic damage in patients with chronic hepatitis B virus (HBV) infection is well known; more effective treatments for this infection are needed. Lamivudine is being studied in immunocompetent and immunosuppressed HBV infected patients. We report a patient suffering from chronic replicative HBV infection after allogeneic BMT, who responded to lamivudine therapy. A 24-year-old woman with CML received an allogeneic BMT from her HLA-identical sister in June 1992. Before transplant, her HBV status demonstrated viral contact without active infection (HBsAb+, HBcAb+ IgG, HBeAb+). Four months after BMT mild chronic liver GVHD appeared, requiring immunosuppressive treatment. Antibodies to HBV completely disappeared post-transplant. Acute icteric hepatitis occurred 2 years later, with HBsAg+, high level of HBV-DNA, HBeAg+ and HBcAb IgM+. Lamivudine 100 mg/day rapidly reduced transaminase levels and effected HBV-DNA disappearance within 2 months. The treatment was well tolerated; no hematological side-effects occurred. This preliminary observation warrants further investigation of lamivudine treatment in bone marrow transplanted patients with active HBV infection.

AB - The risk of severe hepatic damage in patients with chronic hepatitis B virus (HBV) infection is well known; more effective treatments for this infection are needed. Lamivudine is being studied in immunocompetent and immunosuppressed HBV infected patients. We report a patient suffering from chronic replicative HBV infection after allogeneic BMT, who responded to lamivudine therapy. A 24-year-old woman with CML received an allogeneic BMT from her HLA-identical sister in June 1992. Before transplant, her HBV status demonstrated viral contact without active infection (HBsAb+, HBcAb+ IgG, HBeAb+). Four months after BMT mild chronic liver GVHD appeared, requiring immunosuppressive treatment. Antibodies to HBV completely disappeared post-transplant. Acute icteric hepatitis occurred 2 years later, with HBsAg+, high level of HBV-DNA, HBeAg+ and HBcAb IgM+. Lamivudine 100 mg/day rapidly reduced transaminase levels and effected HBV-DNA disappearance within 2 months. The treatment was well tolerated; no hematological side-effects occurred. This preliminary observation warrants further investigation of lamivudine treatment in bone marrow transplanted patients with active HBV infection.

KW - Bone marrow transplantation

KW - Chronic hepatitis B virus infection

KW - Lamivudine

UR - http://www.scopus.com/inward/record.url?scp=0031872819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031872819&partnerID=8YFLogxK

M3 - Article

C2 - 9674862

AN - SCOPUS:0031872819

VL - 21

SP - 1267

EP - 1269

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -